MX336726B - Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3. - Google Patents

Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.

Info

Publication number
MX336726B
MX336726B MX2013003620A MX2013003620A MX336726B MX 336726 B MX336726 B MX 336726B MX 2013003620 A MX2013003620 A MX 2013003620A MX 2013003620 A MX2013003620 A MX 2013003620A MX 336726 B MX336726 B MX 336726B
Authority
MX
Mexico
Prior art keywords
glycogen synthase
inhibitors
synthase kinase
heterocyclic compounds
compounds
Prior art date
Application number
MX2013003620A
Other languages
English (en)
Spanish (es)
Other versions
MX2013003620A (es
Inventor
Wilfried Hornberger
Sean Colm Turner
Margaretha Henrica Maria Bakker
Falko Ernst Wolter
Marcel Van Gaalen
Marjoleen Nijsen
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MX2013003620A publication Critical patent/MX2013003620A/es
Publication of MX336726B publication Critical patent/MX336726B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2013003620A 2010-09-27 2011-09-26 Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3. MX336726B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38684910P 2010-09-27 2010-09-27
PCT/EP2011/066684 WO2012041814A1 (fr) 2010-09-27 2011-09-26 Composés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la glycogène synthase kinase-3

Publications (2)

Publication Number Publication Date
MX2013003620A MX2013003620A (es) 2013-10-28
MX336726B true MX336726B (es) 2016-01-27

Family

ID=44773057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003620A MX336726B (es) 2010-09-27 2011-09-26 Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.

Country Status (7)

Country Link
US (3) US9266855B2 (fr)
EP (1) EP2621914B1 (fr)
JP (1) JP5998142B2 (fr)
CN (1) CN103119035B (fr)
CA (1) CA2810954A1 (fr)
MX (1) MX336726B (fr)
WO (1) WO2012041814A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3102576T1 (sl) 2014-02-03 2019-08-30 Vitae Pharmaceuticals, Llc Inhibitorji dihidropirolopiridina ROR-gama
BR112017007460A2 (pt) 2014-10-14 2017-12-19 Vitae Pharmaceuticals Inc inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
JP6770775B2 (ja) 2015-10-16 2020-10-21 アッヴィ・インコーポレイテッド （３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017087608A1 (fr) 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulateurs de ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (fr) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror gamma
KR20200053481A (ko) 2017-07-24 2020-05-18 비타이 파마슈티컬즈, 엘엘씨 RORγ의 억제제
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
AU779550B2 (en) 1999-04-09 2005-01-27 Meiji Seika Kaisha Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP2004507526A (ja) 2000-08-31 2004-03-11 ファイザー・プロダクツ・インク ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN1317030C (zh) 2001-04-30 2007-05-23 赞塔里斯有限公司 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
ES2254611T3 (es) 2001-05-11 2006-06-16 Pfizer Products Inc. Derivados de tiazol.
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
WO2003035065A1 (fr) 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases
ATE466581T1 (de) 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
SE0104340D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
DE60221283T2 (de) 2001-12-21 2008-03-20 Astrazeneca Ab Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP4681548B2 (ja) 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
ATE536353T1 (de) 2003-08-20 2011-12-15 Vertex Pharma 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
JP2007513155A (ja) 2003-12-04 2007-05-24 スミスクライン ビーチャム コーポレーション 新規化合物
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1586318A1 (fr) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiazolidinones comme inhibiteurs de GSK-3
WO2005099353A2 (fr) 2004-04-19 2005-10-27 Symed Labs Limited Nouveau procede pour preparer du linezolide et des composes associes
CA2569404A1 (fr) 2004-06-04 2005-12-22 Amphora Discovery Corporation Composes a base de quinoleine et d'isoquinoleine presentant une activite d'inhibition d'enzymes utilisant de l'atp et compositions et utilisations de ceux-ci
WO2005123672A2 (fr) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Inhibiteurs de kinase
EP1781653A1 (fr) 2004-07-05 2007-05-09 Astex Therapeutics Limited Pyrazoles 3,4-disubstitutes servant d'inhibiteurs de kinases cyclines dependantes (cdk), ou de kinases aurora ou de glycogene syntases 3 (gsk-3)
ATE429423T1 (de) 2004-07-20 2009-05-15 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
WO2006091737A1 (fr) 2005-02-24 2006-08-31 Kemia, Inc. Modulateurs de l'activite de gsk-3
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
AU2006265205B2 (en) 2005-06-30 2011-06-30 Janssen Pharmaceutica N.V. Cyclic anilino - pyridinotriazines
EP1749523A1 (fr) 2005-07-29 2007-02-07 Neuropharma, S.A. Des inhibiteurs de GSK-3
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
UY29825A1 (es) 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
KR20070077468A (ko) 2006-01-23 2007-07-26 크리스탈지노믹스(주) 단백질 키나아제 활성을 저해하는 이미다조피리딘 유도체,이의 제조방법 및 이를 함유하는 약학 조성물
US20090221576A1 (en) 2006-02-02 2009-09-03 Astrazeneca Ab Global Intellectual Property Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts
WO2007120102A1 (fr) 2006-04-19 2007-10-25 Astrazeneca Ab Nouveaux derives substitues d'oxindole
EP1849785A1 (fr) 2006-04-28 2007-10-31 Neuropharma, S.A. Dérivés de N-(2-Thiazolyl)-amide en tant qu'inhibiteurs de GSK-3
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
MX2009004140A (es) 2006-10-21 2009-07-10 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
DE602007007985D1 (de) 2006-12-19 2010-09-02 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EP2125683B1 (fr) 2006-12-19 2013-10-23 The Board of Trustees of the University of Illinois 3-benzofuranyl-4-indolyl-maléimides en tant qu'inhibiteurs de gsk-3 puissants pour troubles neurodégéneratifs
RU2460725C2 (ru) 2007-02-15 2012-09-10 Ф. Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1
KR20090129479A (ko) 2007-04-18 2009-12-16 아스트라제네카 아베 화합물 2-히드록시-3-[5-(모르폴린-4-일메틸)피리딘-2-일]1ｈ-인돌-5-카르보니트릴 701의 신규 제조 방법
CA2686545C (fr) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Composes substitues de morpholinyle
EP1992624A1 (fr) 2007-05-16 2008-11-19 Sanofi-Aventis Composés de pyrimidonine d'hétéroarylamide
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
WO2009051782A1 (fr) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Étravirine deutérée
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
JP5756011B2 (ja) 2008-04-24 2015-07-29 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Also Published As

Publication number Publication date
JP2013537897A (ja) 2013-10-07
EP2621914B1 (fr) 2016-12-28
CA2810954A1 (fr) 2012-04-05
US20160016932A1 (en) 2016-01-21
US10100048B2 (en) 2018-10-16
US20120077840A1 (en) 2012-03-29
CN103119035B (zh) 2015-09-30
EP2621914A1 (fr) 2013-08-07
US20160194320A1 (en) 2016-07-07
WO2012041814A1 (fr) 2012-04-05
CN103119035A (zh) 2013-05-22
MX2013003620A (es) 2013-10-28
JP5998142B2 (ja) 2016-09-28
US9266855B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
MX2012013197A (es) Inhibidores de indazol de cinasa.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2012004114A (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX336346B (es) Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa.
MX340402B (es) Inhibidores triciclicos de cinasas.
NZ700928A (en) Dna-pk inhibitors
NZ711376A (en) Heteroaryl compounds and uses thereof
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
EP2571876A4 (fr) Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
WO2009117676A3 (fr) Nouveaux dérivés de pipéridine servant d'inhibiteurs de stéaroyle-coa-désaturase
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MY179042A (en) Kinase inhibitors with improved cyp safety profile
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
MX2015000980A (es) Inhibidores de aril lactama cinasa.